PHI OPTICS INC
Champaign, IL · Founded 2009 · CIK 0001579609 · Biotech · Private
Label-free digital staining and imaging system for cell and tissue assays using quantitative phase microscopy
phioptics.com →- Grants
- $4.0M
- 7 awards
- Sector median: 1
- Raised
- $450K
- 3 Form D · Apr 2018
- 102 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201320152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $250,000 | |
| Private capital raised | Form D · SEC | $550,000 | |
| Private capital raised | Form D · SEC | $200,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Label-free classification of cell cycle | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Label-free classification of cell cycle | $225,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Label-free cell viability assays using Phase Imaging with Computational Specificity | $894,309 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Label-free cell viability assays using Phase Imaging with Computational Specificity | $1,544,202 | |
| Federal grant | Department of Health and Human Services · Phase I · Label-free cell cycle classification using Phase Imaging with Computational Specificity | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Label-free cell cycle classification using Phase Imaging with Computational Specificity | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Label-free cell viability assays using Phase Imaging with Computational Specificity | $649,893 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1740 | IMMUNOPHOTONICS INC | — | $18M |
| 1741 | Superluminal Medicines | — | $116M |
| 1742 | Gossamer Bio | — | $728M |
| 1743 | PHI OPTICS INC | — | $450K |
| 1744 | Iambic Therapeutics | — | $323M |
| 1745 | AVT, Inc. | — | $170K |
| 1746 | INFINIFLUIDICS INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Catalin ChiritescuDirector · Executive Officer · Promoter
- Timothy HoerrDirector
- Gabriel PopescuDirector · Executive Officer · Promoter
- Jed TaylorDirector
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.